Abstract
Introduction Differences in amyloid positron emission tomography (PET) radiotracer pharmacokinetics and binding properties lead to discrepancies in amyloid-β uptake estimates. Harmonization of tracer-specific biases is crucial for optimal performance of downstream tasks. Here, we investigated the efficacy of ComBat, a data-driven harmonization model, for reducing tracer-specific biases in regional amyloid PET measurements from [18F]-florbetapir (FBP) and [11C]-Pittsburgh Compound-B (PiB).
Methods One-hundred-thirteen head-to-head FBP-PiB scan pairs, scanned from the same subject within ninety days, were selected from the Open Access Series of Imaging Studies 3 (OASIS-3) dataset. The Centiloid scale, ComBat with no covariates, ComBat with biological covariates, and GAM-ComBat with biological covariates were used to harmonize both global and regional amyloid standardized uptake value ratios (SUVR). Variants of ComBat, including longitudinal ComBat and PEACE, were also tested. Intraclass correlation coefficient (ICC) and mean absolute error (MAE) were computed to measure the absolute agreement between tracers. Additionally, longitudinal amyloid SUVRs from an anti-amyloid drug trial were simulated using linear mixed effects modeling. Differences in rates-of-change between simulated treatment and placebo groups were tested, and change in statistical power/Type-I error after harmonization was quantified.
Results In the head-to-head tracer comparison, ComBat with no covariates was the best at increasing ICC and decreasing MAE of both global summary and regional amyloid PET SUVRs between scan pairs of the same group of subjects. In the clinical trial simulation, harmonization with both Centiloid and ComBat increased statistical power of detecting true rate-of-change differences between groups and decreased false discovery rate in the absence of a treatment effect. The greatest benefit of harmonization was observed when groups exhibited differing FBP-to-PiB proportions.
Conclusion ComBat outperformed the Centiloid scale in harmonizing both global and regional amyloid estimates. Additionally, ComBat improved the detection of rate-of-change differences between clinical trial groups. Our findings suggest that ComBat is a viable alternative to Centiloid for harmonizing regional amyloid PET analyses.
Competing Interest Statement
AS reported receiving personal fees from BrightFocus for serving as a grant reviewer and stock from TheraPanacea outside the submitted work. All remaining authors have no conflicting interests to report.
Funding Statement
BY was supported by the Imaging Science Pathways NIH T32 EB014855 and BrightFocus Foundation grant ADR A2021042S. AS was supported by NIH award R01 AG067103 and BrightFocus Foundation grant ADR A2021042S. Computations were performed using the facilities of the Washington University Research Computing and Informatics Facility, which were partially funded by NIH grants S10OD025200, 1S10RR022984-01A1 and 1S10OD018091-01. Additional support is provided by The McDonnell Center for Systems Neuroscience.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data utilized in this study were obtained from the OASIS-3 open access dataset. Data can be requested at https://sites.wustl.edu/oasisbrains.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Additional comparisons with longitudinal ComBat and PEACE were added; mean standardized absolute error was removed in favor of mean absolute error, and corresponding figures and tables were revised; clinical trial simulation methodology was slightly modified, and corresponding figures and tables were revised; Table 1 modified; supplementary material were updated to include new results
Data Availability
Data utilized in this study were obtained from the OASIS-3 open access dataset. Data can be requested at https://sites.wustl.edu/oasisbrains. Code for this study will be made publicly available at https://github.com/sotiraslab. All statistical analyses and simulation experiments were implemented using R version 4.4.0 and python version 3.10.10. The neuroharmonize python package (https://github.com/rpomponio/neuroHarmonize) was used to train and apply ComBat and GAM-ComBat models, and the longCombat R package (https://github.com/jcbeer/longCombat) was used to train and apply longitudinal ComBat.
List of Abbreviations
- PET
- positron emission tomography
- FBP
- [18F]-florbetapir
- PiB
- [11C]-Pittsburgh Compound-B
- OASIS-3
- Open Access Series of Imaging Studies 3
- SUVR
- standardized uptake value ratio
- ICC
- intraclass correlation coefficient
- MAE
- mean absolute error
- AD
- Alzheimer’s disease
- ROI
- region-of-interest
- CL
- Centiloid
- MRI
- magnetic resonance imaging
- APOE
- apolipoprotein-ε4
- GAM
- generalized additive model
- LME
- linear mixed effects
- CDR
- Clinical Dementia Rating
- PEACE
- Probabilistic Estimation for Across-batch Compatibility Enhancement.
